All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous systemic treatment (%) previous systemic treatment NO (%) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIa stage IIIb stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), immune chekpoint inhibitors vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs I ; all population), 2015 0.55 [0.42; 0.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.65 [0.53; 0.80]
CheckMate 069 (all population), 2015 0.74 [0.43; 1.27]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
CheckMate 238, 2017 0.87 [0.66; 1.14]
IMspire-170, 2020 1.06 [0.69; 1.62]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
0.75 [0.66 ; 0.87 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 238, 2017, IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 11 60% 5,796 low low deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.52 [0.42; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.83 [0.67; 1.03]
KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.66 [0.57 ; 0.77 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 58% 3,002 low not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.35; 0.51]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.79 [0.65; 0.97]
CheckMate 069 (all population), 2015 0.36 [0.23; 0.57]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.55 [0.45 ; 0.67 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 76% 3,177 low not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.31; 0.57]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.74 [0.60; 0.92]
CheckMate 069 (all population), 2015 0.38 [0.23; 0.63]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69]
IMspire-170, 2020 1.15 [0.88; 1.50]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.60 [0.49 ; 0.75 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 79% 4,459 low low RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.40 [0.20; 0.79]
0.57 [0.37 ; 0.87 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 41% 1,021 low not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
IMspire-170, 2020 0.91 [0.63; 1.32]
1.06 [0.82 ; 1.37 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMspire-170, 2020 2 10% 1,173 low not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs I ; all population), 2015 6.11 [3.59; 10.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.76 [1.28; 2.41]
CheckMate 069 (all population), 2015 15.08 [8.07; 28.17]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38]
IMspire-170, 2020 0.77 [0.50; 1.17]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
2.88 [1.64 ; 5.06 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 11 92% 4,999 low low objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs I ; all population), 2015 6.35 [4.38; 9.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.96 [4.16; 8.54]
CheckMate 069 (all population), 2015 12.20 [4.41; 33.76]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60]
5.92 [4.15 ; 8.45 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 6 52% 2,174 low not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
IMspire-170, 2020 14.27 [3.34; 61.03]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
2.25 [0.33 ; 15.15 ] CheckMate 238, 2017, IMspire-170, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 3 87% 1,852 low not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
IMspire-170, 2020 4.03 [2.70; 6.00]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
1.03 [0.21 ; 5.01 ] CheckMate 238, 2017, IMspire-170, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 3 98% 1,852 low not evaluable AE leading to death (grade 5)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
IMspire-170, 2020 1.39 [0.43; 4.44]
1.35 [0.44 ; 4.13 ] IMMUNED (NI vs N) EXPLORATORY, 2020, IMspire-170, 2020 2 0% 547 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
1.25 [0.02 ; 89.58 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 99% 1,016 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
1.09 [0.01 ; 103.30 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 98% 1,016 low not evaluable SAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 3.69 [1.68; 8.08]
3.69 [1.68 ; 8.08 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable SAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 3.48 [1.58; 7.66]
3.48 [1.58 ; 7.66 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable STRAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 5.69 [2.43; 13.31]
KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
1.26 [0.42 ; 3.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 91% 1,178 moderate not evaluable STRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 4.68 [1.93; 11.38]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
4.03 [1.73 ; 9.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 low not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs I ; all population), 2015 3.70 [1.95; 7.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.58 [1.88; 6.81]
CheckMate 069 (all population), 2015 0.75 [0.19; 2.97]
CheckMate 238, 2017 0.25 [0.15; 0.43]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.07 [1.04; 24.68]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
1.55 [0.94 ; 2.54 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 88% 5,334 low low TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs I ; all population), 2015 3.83 [2.74; 5.36]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.82 [3.41; 6.80]
CheckMate 069 (all population), 2015 3.77 [1.71; 8.31]
CheckMate 238, 2017 0.20 [0.14; 0.27]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.66 [2.91; 15.27]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
1.61 [0.76 ; 3.40 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 97% 5,334 low low TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.18 [0.40 ; 3.47 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,683 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [2.72; 5.85]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.85 [3.25; 7.24]
CheckMate 069 (all population), 2015 4.18 [1.76; 9.91]
CheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19]
CheckMate 238, 2017 0.12 [0.08; 0.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.33 [4.34; 29.62]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.81 [0.76 ; 4.27 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF wild type), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 10 97% 4,931 low low TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs I ; all population), 2015 2.72 [1.82; 4.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.10 [3.17; 8.19]
CheckMate 069 (all population), 2015 4.14 [1.59; 10.74]
CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (NI vs N) EXPLORATORY, 2020 11.38 [3.94; 32.84]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.66 [0.58 ; 4.75 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 96% 4,823 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.24 [0.01; 7.31]
CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.58 [0.18 ; 1.87 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
2.06 [0.07 ; 62.55 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 0.24 [0.02; 2.68]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.48 [0.67 ; 3.29 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 8 0% 4,267 low not evaluable Alopecia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.10 ; 9.21 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.34 [0.24 ; 7.35 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.01 [0.18; 22.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.25 [0.01; 5.62]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.00 [0.34 ; 3.00 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.25 [0.03; 2.24]
KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.43 [0.16 ; 1.15 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,986 low not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.81 [0.11 ; 5.75 ] CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,318 moderate not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs I ; all population), 2015 1.08 [0.61; 1.93]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 9.36 [2.80; 31.26]
CheckMate 069 (all population), 2015 2.94 [0.81; 10.66]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
0.94 [0.41 ; 2.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 9 83% 4,429 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.11 ; 8.13 ] CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,207 moderate not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.25 [0.01; 5.54]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.98 [0.23 ; 4.22 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,052 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 4.01 [0.45; 36.11]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 8.09 [0.43; 153.69]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.85 [0.55 ; 6.30 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,192 low serious Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.24 [0.17 ; 8.83 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (3 week), 2015 3 0% 1,549 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs I ; all population), 2015 1.66 [0.90; 3.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.45 [1.60; 7.41]
CheckMate 069 (all population), 2015 0.98 [0.31; 3.04]
CheckMate 238, 2017 0.15 [0.07; 0.34]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
0.88 [0.47 ; 1.65 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 79% 5,334 low low Dizziness TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.37 [0.62; 3.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.29 [0.63 ; 2.67 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,052 low serious Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.94 [0.63 ; 6.00 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,192 low not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
CheckMate 069 (all population), 2015 1.24 [0.23; 6.63]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.50 [0.62; 48.70]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
1.31 [0.39 ; 4.40 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 66% 1,488 low not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
1.01 [0.09 ; 11.20 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 837 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs I ; all population), 2015 4.45 [1.26; 15.77]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.48 [1.26; 15.87]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
1.59 [0.74 ; 3.42 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 32% 4,097 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
4.19 [0.18 ; 95.03 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
CheckMate 069 (all population), 2015 2.22 [0.77; 6.34]
CheckMate 238, 2017 0.10 [0.05; 0.20]
IMMUNED (NI vs N) EXPLORATORY, 2020 9.36 [1.13; 77.61]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
1.06 [0.28 ; 4.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 5 93% 2,393 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
4.19 [0.18 ; 95.03 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 1.98 [0.09; 44.77]
CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.82 [0.28 ; 2.36 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 10.08 [0.55; 185.32]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.15 [0.55; 186.51]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.31 [0.64; 17.15]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
3.26 [1.50 ; 7.12 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 9 0% 4,429 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 15.93 [0.93; 273.74]
CheckMate 238, 2017 0.15 [0.07; 0.32]
IMMUNED (NI vs N) EXPLORATORY, 2020 7.53 [1.60; 35.49]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
2.30 [0.16 ; 33.53 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 4 89% 1,667 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
CheckMate 238, 2017 2.01 [0.07; 59.97]
3.72 [0.39 ; 35.19 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 2 0% 1,631 low not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.05 [0.30; 121.25]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 6.40 [0.31; 130.93]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.74 [0.55 ; 5.45 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.28; 3.47]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.06 [0.59; 43.61]
CheckMate 069 (all population), 2015 0.48 [0.07; 3.51]
CheckMate 238, 2017 0.18 [0.04; 0.81]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
0.65 [0.34 ; 1.23 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 21% 5,334 low low Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
1.03 [0.35 ; 3.03 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 0% 5,334 low low Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs I ; all population), 2015 9.98 [2.31; 43.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.68 [1.96; 22.80]
CheckMate 069 (all population), 2015 7.32 [0.41; 131.94]
CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
1.80 [0.59 ; 5.47 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 71% 5,334 low low Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs I ; all population), 2015 5.78 [2.20; 15.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.29 [2.52; 21.10]
CheckMate 069 (all population), 2015 10.83 [0.62; 189.76]
CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (NI vs N) EXPLORATORY, 2020 5.47 [1.46; 20.45]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
1.92 [0.65 ; 5.63 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 80% 5,334 low low Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs I ; all population), 2015 3.04 [1.54; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.60 [1.37; 4.95]
CheckMate 069 (all population), 2015 4.19 [0.51; 34.53]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.01 [0.75; 12.00]
2.32 [1.59 ; 3.39 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020 6 0% 2,851 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
2.37 [0.21 ; 27.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 837 low not evaluable Leucopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.68 [0.70 ; 4.02 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 5% 4,823 low not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.06; 16.70]
1.02 [0.06 ; 16.70 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 0.16 [0.01; 3.31]
0.16 [0.01 ; 3.31 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.02; 15.35]
KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.91 [0.27 ; 3.09 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,192 low not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.10 ; 9.21 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 3.53 [0.73; 17.15]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 14.30 [0.81; 253.04]
CheckMate 069 (all population), 2015 0.48 [0.03; 7.91]
CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.86 [0.70 ; 4.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
IMMUNED (NI vs N) EXPLORATORY, 2020 0.50 [0.04; 5.68]
1.76 [0.12 ; 26.45 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 51% 837 low not evaluable Neutropenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.95 [0.10 ; 9.21 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.50 [0.11 ; 19.59 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 837 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.57 [0.07 ; 4.44 ] IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,178 moderate not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
2.96 [0.30 ; 29.40 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 2 0% 837 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 3.00 [0.31; 29.00]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 0.98 [0.09; 11.08]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.72 [0.66 ; 4.49 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 3,918 low not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.78 [0.18 ; 3.32 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,807 low not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.10 [0.73; 50.95]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
1.44 [0.60 ; 3.45 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 10 0% 5,334 low low Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (NI vs N) EXPLORATORY, 2020 4.19 [0.18; 95.03]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.48 [0.49 ; 4.49 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 8 0% 4,097 low not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 2.02 [0.68; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.30 [1.31; 80.93]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.35 [0.13; 0.98]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
1.35 [0.56 ; 3.28 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 9 47% 5,223 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 1.00 [0.02; 50.62]
0.99 [0.08 ; 12.98 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017 2 0% 1,045 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 069 (all population), 2015 1.48 [0.15; 14.67]
CheckMate 238, 2017 0.12 [0.01; 2.36]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.15 [0.22 ; 6.12 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 4 23% 1,882 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
CheckMate 069 (all population), 2015 9.64 [0.55; 170.02]
CheckMate 238, 2017 0.18 [0.07; 0.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 3.17 [0.32; 31.48]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.56 [0.33; 7.34]
1.23 [0.32 ; 4.75 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 5 74% 2,393 low serious Stomatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.02 [0.02 ; 52.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 2.06 [0.07; 62.55]
2.06 [0.07 ; 62.55 ] IMMUNED (NI vs N) EXPLORATORY, 2020 1 0% 111 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
1.59 [0.32 ; 7.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMMUNED (NI vs N) EXPLORATORY, 2020 5 0% 2,711 low serious Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.78 [0.12 ; 5.14 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, IMMUNED (NI vs N) EXPLORATORY, 2020, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 1,904 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.50 [0.02; 14.93]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
IMMUNED (NI vs N) EXPLORATORY, 2020 1.02 [0.02; 52.25]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.01; 17.42]
0.77 [0.17 ; 3.50 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, IMMUNED (NI vs N) EXPLORATORY, 2020, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 6 0% 2,636 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-23 09:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
